Matteo Simonelli, Head of Early-Drug Development in Solid Tumors and Neuro-Oncology at IRCCS Humanitas Research Hospital, Associate Professor of Medical Oncology at Humanitas University, shared a post on LinkedIn:
“Super nice and inspiring Developmental Therapeutics mini oral session at ESMO2025 day one, all about novel ADCs, agents exploiting sinthetic letality, and next-generation KRAS inhibitors!
I had the chance to present the results from the monotherapy arms of the Phase I KANDLELIT-001 study, exploring the safety and preliminary efficacy of MK-1084, a highly potent and selective covalent KRASG12C inhibitor, in pretreated patients with advanced solid tumors focusing on those other than NSCLC and CRC.
Great tolerability and really exciting signals of activity in hepato-biliary tract and pancreatic cancers!”
Follow the latest ESMO 2025 news on OncoDaily.
